Endo International plc

Endo International plc
Public
Traded as NASDAQ: ENDP
S&P 400 Component
Industry Pharmaceutical
Headquarters Dublin, Ireland and Malvern, Pennsylvania, U.S.
Website www.endo.com

Endo International plc is a generics and specialty branded pharmaceutical company. It was created as a result of a management buyout from DuPont Merck in 1997 led by Carol Ammon.[1]

Acquisitions

In 2009, Endo bought Indevus Pharmaceuticals to diversify into endocrinology and oncology.[2] The company entered the male hypogonadism market later in 2010 with Fortesta 2% gel.[2]

In November 2013, Endo agreed to purchase Paladin Labs Inc for about $1.6 billion to gain access to the Canadian market as well as expand into emerging markets.[3][4]

In October 2014, Endo said it would buy Auxilium Pharmaceuticals for $2.6 billion.[5]

In 2015, Endo acquired the specialty generics and sterile injectables company Par Pharmaceutical for $8.05 billion.[6]

Acquisition attempts

In early 2014, Endo sought to acquire NuPathe, a speciality pharmaceutical developer, for $105 million.[7] However, Teva prevailed in this acquisition with a substantially higher bid.[8]

References

  1. ↑ Schneiderman, R.M. (9 April 2007). "Ammon Exits Endo". Forbes.
  2. 1 2 Associated Press (2009-01-06). "Endo to buy Indevus". The Boston Globe. Retrieved 2009-06-28.
  3. ↑ Rubin, Ben Fox (5 November 2013). "Endo Health to Buy Paladin Labs for $1.6 Billion". Wall Street Journal.
  4. ↑ "Endo Health to Buy Specialty Drug Maker for $1.6 Billion". New York Times Dealbook. November 5, 2013.
  5. ↑ "Endo Scores with $2.6B Offer for Auxilium, Which Ends QLT Deal | GEN Genetic Engineering & Biotechnology News - Biotech from Bench to Business | GEN". GEN. October 9, 2014.
  6. ↑ Bray, Chad (18 May 2015). "Endo International to Pay $8.05 Billion for Par Pharmaceutical". The New York Times.
  7. ↑ "Endo to Purchase NuPahte for $150M+". News: Industry Watch. Gen. Eng. Biotechnol. News (paper). 34 (2). January 15, 2014. p. 10.
  8. ↑ "Teva Outbids Endo, Acquires NuPathe for $144M+". News: Industry Watch. Gen. Eng. Biotechnol. News (paper). 34 (4). February 15, 2014. p. 10.
This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.